Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Sunday, August 29, 2021

BMP2 downregulates urokinase-type plasminogen activator via p38 MAPK: Implications in C2C12 cells myogenic differentiation

xlomafota13 shared this article with you from Inoreader
Via histochem

pubmed-meta-image.png

Acta Histochem. 2021 Aug 23;123(6):151774. doi: 10.1016/j.acthis.2021.151774. Online ahead of print.

ABSTRACT

Bone morphogenetic protein (BMP)2 strongly affects the differentiation program of myoblast cells by inhibiting myogenesis and inducing osteogenic differentiation. In turn, extracellular matrix (ECM) proteinases, such as urokinase-type plasminogen activator (uPA), can influence the fate of muscle stem cells by participating in ECM reorganization. Although both BMP2 an d uPA have antagonistic roles in muscles cells differentiation, no connection between them has been elucidated so far. This study aims to determine whether BMP2 regulates uPA expression in the myogenic C2C12 cell line and its impact on muscle cell fate differentiation. Our results showed that BMP2 did not modify C2C12 cell proliferation in a growth medium or myogenic differentiation medium. Although BMP2 inhibited myogenesis and induced osteogenesis, these effects were achieved with different doses of BMP2. Low concentrations of BMP2 blocked myogenesis, while a higher concentration was needed to induce osteogenesis. Reduced uPA expression was noticed alongside myogenic inhibition at low concentrations of BMP2. BMP2 activated p38 MAPK signaling to inhibit uPA activity. Furthermore, ectopic human uPA expression reduced BMP2's ability to inhibit the myogenic differentiation of C2C12 cells. In conclusion, BMP2 inhibits uPA expression through p38 MAPK and in vitro myogenesis at non-osteo genic concentrations, while uPA ectopic expression prevents BMP2 from inhibiting myogenesis in C2C12 cells.

PMID:34450502 | DOI:10.1016/j.acthis.2021.151774

View on the web

No comments:

Post a Comment